ABVC BIOPHARMA, INC.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
ABVC$0.99-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
Our Consolidated Financial Statements and Notes thereto and the report of Simon & Edward, LLP, our independent registered public accounting firm, are set forth on pages F-1 through F-41 of this Report.
| PAGE | F-2 | REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID 2485) |
|---|---|---|
| PAGE | F-5 | CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2024 AND DECEMBER 31, 2023. |
| PAGE | F-6 | CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE YEARS ENDED DECEMBER 31, 2024 AND DECEMBER 31, 2023. |
| PAGE | F-7 | CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND DECEMBER 31, 2023. |
| PAGES | F-8 | CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) FOR THE YEARS ENDED DECEMBER 31, 2024 AND DECEMBER 31, 2023. |
| PAGES | F-9 | NOTES TO CONSOLIDATED FINANCIAL STATEMENTS. |
17506 Colima Road, Ste 101, Rowland Heights, CA 91748 Tel: +1 (626) 581-0818 Fax: +1 (626) 581-0809
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.